Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 13
Phase 22

Trial Status

Recruiting3

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT06675123Phase 1Recruiting
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
PrincipalinvestigatorStart date: 2026-09-29
NCT05861050Phase 1/2Recruiting
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Blastoid Variant Mantle Cell LymphomaMantle Cell LymphomaPleomorphic Variant Mantle Cell Lymphoma
PrincipalinvestigatorStart date: 2023-08-10
NCT07578077Phase 1/2Recruiting
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Luhua (Michael) Wang

M.D. Anderson Cancer Center

Moderately Similar
13 trials

Shared therapeutic areas:

Lymphoma, Mantle-CellRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score30%

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Recurrent Mantle Cell LymphomaLymphoma, Mantle-Cell

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score12%

Isidro Jarque, MD

Hospital Universitario La Fe

Related
1 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score6%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score6%

Maria José Ramírez Sánchez, MD

Hospital del SAS Jerez

Related
1 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score6%

Secundino Ferrer, MD

Hospital Dr. Peset

Related
1 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score6%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

Related
2 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score6%

Antonio Gutiérrez, MD

Hospital Son Espasses

Related
1 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score6%

Ryotaro Nakamura

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Recurrent Mantle Cell Lymphoma

Worked with same sponsors:

City of Hope Medical CenterNational Cancer Institute (NCI)
Similarity Score6%

Jun Zhu, PhD

Peking University Cancer Hospital & Institute

Related
5 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score6%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT06675123Phase 1PrincipalInvestigator

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Recruiting
NCT05861050Phase 1/2PrincipalInvestigator

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Blastoid Variant Mantle Cell LymphomaMantle Cell LymphomaPleomorphic Variant Mantle Cell Lymphoma
Recruiting
NCT07578077Phase 1/2PrincipalInvestigator

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Recruiting

All 3 trials loaded